Law360, New York (August 13, 2007, 12:00 AM ET) -- Locked in a battle over bone cancer drugs Aredia and Zometa, Novartis Pharmaceutical Corp. has asked the district judge overseeing the multidistrict product liability litigation to break apart a current class of plaintiffs and allow them to pursue their claims individually.
The pharmaceutical giant filed a request Friday to have the court sever the class in the case, arguing that the plaintiffs should not still be fused together in the wake of a recent dismissal of allegations.
“Because plaintiffs do not meet the standard for permissive...
Novartis Seeks To Fracture Class In Bone Drug Suit
To view the full article, take a free trial now.
